Skip to content
Bafna Pharmaceuticals logo

Bafna Pharmaceuticals

BAFNAPH NSE
₹451.60 8.85 (2.00%)
Market Cap
₹1,068 Cr
P/E
137.26

Bafna Pharmaceuticals (BAFNAPH) share price was ₹451.60 at the 28 Oct 2026 close; market capitalisation ₹1,068 Cr; P/E (TTM) 137.26; sector Healthcare. The share price rose 233.7% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 23.2% year on year to ₹26.58 Cr and net profit fell 97.6% year on year to ₹0.08 Cr (compared with Jun 2025). Promoters held 75.00% of Bafna Pharmaceuticals in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 35/100 (Poor) as of 28 Oct 2026.

Close 28 Oct 2026 ₹451.60 +316.25 +233.65% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹1,068 Cr
P/E (TTM)
137.26
EBITDA
₹1.50 Cr
Return on Equity
-3.68%
Debt to Equity
0.39
Book Value
₹40.64
EPS (TTM)
₹3.29
52W High
₹479.95
52W Low
₹94.77

Price-based figures as of 28 Oct 2026, 15:14 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Bafna Pharmaceuticals (this company)
₹451.60137.261,068 Cr11.110.00%-3.68%-3.30%40 Cr8 Cr
Median 8 companies₹1,561.5553.201,17,574 Cr7.240.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
35 Poor
Overall score
Data confidence 98/100
surveillance:ASM2

Category scores

Quality Weak 39
Returns, margins, earnings quality 22%
Valuation Poor 17
Cheap vs sector & own history 24%
Growth Poor 8
Sales & profit trajectory 9%
Financial Health Weak 42
Solvency, leverage, coverage 9%
Momentum Strong 99
Trend strength, vol-adjusted 12%
Ownership Average 49
FII/DII/promoter flows 24%
Capped: a governance trigger overrides the fundamentals here (surveillance:ASM2 ≤ 50).

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Weaknesses

5
  • Stock is trading at 9.50 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Tax rate seems low
  • Company has a low return on equity of 9.88% over last 3 years.
  • Earnings include an other income of Rs.6.07 Cr.

Technical Indicators

Oscillators

BearishNeutralBullish

Bullish

Bearish
2
Neutral
4
Bullish
3

Overall

BearishNeutralBullish

Bullish

Bearish
2
Neutral
4
Bullish
13

Moving Averages

BearishNeutralBullish

Bullish

Bearish
0
Neutral
0
Bullish
10

Growth Rate

Revenue Growth
-2.95% lower than 3Y

change over 1 year

Net Income Growth
-90.21% lower than 3Y

change over 1 year

Cash Flow Change
—

EBITDA Margin Change
-112%

change over 1 year Operating margin 3.35% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
41.95
40.68
28.44
41.4
33.29
40.32
33.19
39.06
34.62
35.47
38.29
42.24
26.58
Expenses
35.66
36.67
30.51
38.51
32.08
36.53
30.13
35.95
29.55
31.19
35.24
38.69
25.69
Operating Profit
6.29
4.01
-2.07
2.89
1.21
3.79
3.06
3.11
5.07
4.28
3.05
3.55
0.89
OPM %
14.99%
9.86%
-7.28%
6.98%
3.63%
9.4%
9.22%
7.96%
14.64%
12.07%
7.97%
8.4%
3.35%
Other Income
1.87
0.16
0.98
0.52
0.16
1.02
0.18
-0.76
0.6
1.18
1.22
1.76
1.91
Interest
0.6
0.44
0.58
0.68
0.65
0.62
0.64
0.82
0.91
0.86
0.86
1.03
0.94
Depreciation
1.21
1.24
1.27
1.27
1.44
1.58
1.66
0.22
1.37
1.47
1.57
1.66
1.78
PBT
6.35
2.49
-2.94
1.46
-0.72
2.61
0.94
1.31
3.39
3.13
1.84
2.62
0.08
Tax %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
-4.96%
0%
Net Profit
6.35
2.48
-2.94
1.46
-0.72
2.62
0.95
1.31
3.39
3.12
1.84
2.75
0.08
EPS (₹)
2.68
1.05
-1.24
0.62
-0.3
1.11
0.4
0.55
1.43
1.32
0.78
1.16
0.03
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
100
85
65
46
44
42
71
85
115
152
146
151
143
Expenses
116
82
70
81
57
41
61
73
100
141
135
135
131
Operating Profit
-16
3
-5
-35
-13
1
10
12
16
11
11
16
12
OPM %
-16%
3.3%
-8%
-77%
-30%
2.9%
14%
14%
14%
7%
8%
11%
8%
Other Income
40
1
1
31
0
-23
1
0
3
4
1
5
6
Interest
12
12
11
7
2
0
1
1
2
2
3
4
4
Depreciation
5
4
4
4
3
3
4
5
5
5
5
6
6
PBT
6
-13
-19
-14
-18
-25
6
5
12
7
4
11
8
Tax %
0%
-3%
-4%
15%
8%
0%
0%
0%
2%
0%
0%
-1%
—
Net Profit
6
-12
-18
-16
-20
-25
6
5
11
7
4
11
8
EPS (₹)
3.28
-6.53
-9.9
-6.95
-8.34
-107
2.46
2.21
4.79
3.11
1.75
4.69
3.29
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
19
19
19
24
24
2
24
24
24
24
24
24
Reserves
53
41
26
17
-3
49
33
38
50
57
61
72
Borrowings
64
80
82
47
46
3
15
11
23
24
28
37
Other Liabilities
50
45
40
40
54
17
14
17
33
42
40
42
Total Liabilities
185
185
167
128
121
71
86
90
130
148
153
176
Fixed Assets
49
47
43
40
37
35
36
39
40
40
59
82
CWIP
0
0
0
0
0
0
1
0
2
12
7
3
Investments
18
18
18
1
1
0
0
0
0
0
0
0
Other Assets
118
120
106
86
82
36
50
51
88
95
87
91
Total Assets
185
185
167
128
121
71
86
90
130
148
153
176
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
9
-3
14
-7
-1
-34
-14
10
5
9
22
15
Investing
56
-1
-8
38
4
33
-5
-7
-7
-15
-21
-22
Financing
-66
4
-5
-31
-2
7
12
-5
10
-1
1
6
Net Cash Flow
0
0
0
0
0
6
-7
-2
8
-6
2
-1
Free Cash Flow
2
-5
20
40
-1
-36
-20
2
-2
-6
0
-10
CFO/OP
-74
-106
-263
20
8
-2,786
-132
83
32
87
194
94
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
303
291
302
195
208
52
49
63
130
109
101
106
Inventory Days
66
92
118
102
122
208
154
185
129
125
127
129
Days Payable
149
169
164
265
517
229
107
113
165
149
140
139
Cash Conversion Cycle
220
214
255
31
-188
31
96
135
94
84
88
96
Working Capital Days
56
125
-36
-108
-210
89
121
123
104
92
74
74
ROCE %
-13%
0%
-6%
-35%
-21%
-3%
10%
11%
16%
9%
8%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Bafna Pharmaceuticals insights

68 extracted metrics + investor summaries across FY09–FY27.

Shareholding Pattern

Others3.69%Promot.75.00%FIIs9.34%Public11.97%As ofSep 2026

Documents

Frequently Asked Questions about Bafna Pharmaceuticals

What does Bafna Pharmaceuticals Ltd do?
Incorporated in 1981, Bafna Pharmaceuticals Ltd manufactures finished pharmaceutical formulations[1]
Where is Bafna Pharmaceuticals Ltd (BAFNAPH) listed?
Bafna Pharmaceuticals Ltd trades as BAFNAPH on the NSE and under code 532989 on the BSE.
Which sector does Bafna Pharmaceuticals Ltd belong to?
Bafna Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd has a market capitalisation of ₹1,068 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd trades at a PE ratio of 137.26 as of 28 Oct 2026, on earnings per share of ₹3.29, against a book value of ₹40.64 per share.
What is the 52-week high and low of Bafna Pharmaceuticals Ltd?
Over the last 52 weeks Bafna Pharmaceuticals Ltd has traded between ₹94.77 and ₹479.95 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd reported a return on equity of -3.68%. Its debt-to-equity ratio is 0.39.

Company Information

Incorporated in 1981, Bafna Pharmaceuticals Ltd manufactures finished pharmaceutical formulations[1]

Website bafnapharma.com
CEO Mr. Bansilal Mahaveer Chand Bafna
Employees 406
Listed 2020-02-27
Face Value ₹ 10
Shares Outstanding 2,36,56,335

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BAFNAPH.md for Bafna Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month